C Austad1,2, T K Kvien1, I C Olsen1, T Uhlig1. 1. a Department of Rheumatology , Diakonhjemmet Hospital , Oslo , Norway. 2. b Department of Rheumatology , Drammen Hospital , Drammen , Norway.
Abstract
OBJECTIVES: To explore factors related to sleep disturbance in patients with rheumatoid arthritis (RA). METHOD: Cross-sectional data from 986 patients in the Oslo RA Register (ORAR) collected in 2009 were included. Sleep problems were assessed by four measures: the Medical Outcomes Study (MOS) sleep disturbance scale, and the sleep components of the Rheumatoid Arthritis Impact of Disease (RAID) score, the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and the 15-dimensional quality of life questionnaire (15D). Patient-reported outcomes (PROs) were recorded using standard questionnaires for physical and mental function [the HAQ and the MOS 36-item Short-Form Health Survey (SF-36), disease activity (the RA Disease Activity Index, RADAI), utility (SF-6D), and visual analogue scales (VAS) for pain, fatigue, and disease activity]. Demographics including comorbidity were collected. Information on use of medication for RA and sleep disturbance was obtained using checklists. Multivariate analyses were used to identify factors independently associated with sleep problems by four different measures. RESULTS: The mean (standard deviation, SD) age of the patients was 59.4 (12.5) years, 76.9% were females, and the mean (SD) disease duration was 13.7 (10.7) years. The correlation between the various sleep measures was high (r2 = 0.71-0.78). Sleep disturbance was moderately correlated to pain (r2 = 0.41-0.61), fatigue (r2 = 0.44-0.58), physical function (r2 = 0.33-0.48), RADAI (r2 = 0.42-0.55), and utility (r2 = 0.49-0.61). RAID sleep demonstrated the highest correlation with other PROs. RADAI, fatigue, the mental component score of SF-36, physical function, body mass index (BMI), and use of Z-drugs/benzodiazepines were independently associated with two or more measures of sleep problems (all p < 0.001). CONCLUSIONS: Sleep disturbance measured by four different measures was independently related to other PROs including fatigue, pain, and disease activity in RA patients.
OBJECTIVES: To explore factors related to sleep disturbance in patients with rheumatoid arthritis (RA). METHOD: Cross-sectional data from 986 patients in the Oslo RA Register (ORAR) collected in 2009 were included. Sleep problems were assessed by four measures: the Medical Outcomes Study (MOS) sleep disturbance scale, and the sleep components of the Rheumatoid Arthritis Impact of Disease (RAID) score, the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and the 15-dimensional quality of life questionnaire (15D). Patient-reported outcomes (PROs) were recorded using standard questionnaires for physical and mental function [the HAQ and the MOS 36-item Short-Form Health Survey (SF-36), disease activity (the RA Disease Activity Index, RADAI), utility (SF-6D), and visual analogue scales (VAS) for pain, fatigue, and disease activity]. Demographics including comorbidity were collected. Information on use of medication for RA and sleep disturbance was obtained using checklists. Multivariate analyses were used to identify factors independently associated with sleep problems by four different measures. RESULTS: The mean (standard deviation, SD) age of the patients was 59.4 (12.5) years, 76.9% were females, and the mean (SD) disease duration was 13.7 (10.7) years. The correlation between the various sleep measures was high (r2 = 0.71-0.78). Sleep disturbance was moderately correlated to pain (r2 = 0.41-0.61), fatigue (r2 = 0.44-0.58), physical function (r2 = 0.33-0.48), RADAI (r2 = 0.42-0.55), and utility (r2 = 0.49-0.61). RAID sleep demonstrated the highest correlation with other PROs. RADAI, fatigue, the mental component score of SF-36, physical function, body mass index (BMI), and use of Z-drugs/benzodiazepines were independently associated with two or more measures of sleep problems (all p < 0.001). CONCLUSIONS: Sleep disturbance measured by four different measures was independently related to other PROs including fatigue, pain, and disease activity in RApatients.
Authors: Vibeke Strand; Margaret Michalska; Christine Birchwood; Jinglan Pei; Katie Tuckwell; Rebecca Finch; Cem Gabay; Arthur Kavanaugh; Graeme Jones Journal: RMD Open Date: 2017-09-14
Authors: Shilabant Sen Sribastav; He Peiheng; Long Jun; Li Zemin; Wei Fuxin; Wang Jianru; Liu Hui; Wang Hua; Zheng Zhaomin Journal: PeerJ Date: 2017-05-16 Impact factor: 2.984
Authors: K M Latocha; K B Løppenthin; M Østergaard; P J Jennum; R Christensen; M Hetland; H Røgind; T Lundbak; J Midtgaard; B A Esbensen Journal: Trials Date: 2020-05-29 Impact factor: 2.279
Authors: Ricardo J O Ferreira; Laure Gossec; Cátia Duarte; Joanne K Nicklin; Sarah Hewlett; J A P da Silva; Mwidimi Ndosi Journal: Qual Life Res Date: 2018-08-01 Impact factor: 4.147
Authors: Brandon Becker; Kimberly Raymond; Carol Hawkes; April Mitchell Foster; Andrew Lovley; Cory Saucier; Avery A Rizio; Jakob Bue Bjorner; Mark Kosinski Journal: J Patient Rep Outcomes Date: 2021-07-06
Authors: Vibeke Strand; Margaret Michalska; Christine Birchwood; Jinglan Pei; Katie Tuckwell; Rebecca Finch; Alan J Kivitz; Josef S Smolen; Gerd R Burmester Journal: RMD Open Date: 2018-06-17